| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 1833.6 | 1800.3 | 1486.9 |
| Other income | 69.0 | 61.2 | 84.2 |
| Total income | 1902.6 | 1861.5 | 1571.0 |
| Profit before exceptional items & tax | 430.9 | 435.0 | 283.9 |
| Profit before tax | 430.9 | 435.0 | 283.9 |
| Net profit | 290.8 | 317.0 | 183.7 |
| Operating margin | 22.6% | 23.4% | 18.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +58.30% |
|---|---|
| Net profit, quarter on quarter | -8.30% |
| Revenue, year on year | +23.30% |
| Operating profit, year on year | +81.20% |
| Operating profit, quarter on quarter | -3.20% |
NSE results filing, NSE: GLAND. Figures extracted from the filing.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,169.60
- Market cap
- ₹52,302 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 46.3×Sector 42.0×
- Promoter holding
- 45.75%-6.02% QoQ
- FII holding
- 10.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹18,336 Mn (+23% YoY), PAT ₹2,908 Mn (+58%), adj. EBITDA margin 27%. US CDMO and launches lead; India and RoW weak.
Gland Pharma Results Update
Gland Pharma reported Q2FY27 revenue of Rs. 18,336 Mn, up 23% YoY, and PAT of Rs. 2,908 Mn, up 58% YoY. The press release accompanies its quarterly financial results filing.
Gland Pharma Regulatory Approval
Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.
Gland Pharma Management Change
Gland Pharma appointed Ajay Sahni as CEO of its wholly-owned subsidiary Gland Pharma International Pte. Ltd, effective 2 November 2026. He will lead the Cenexi business.
Gland Pharma Business Update
Gland Pharma reports that USFDA concluded an unannounced cGMP inspection at its Dundigal formulation facility with four procedural Form 483 observations. No monetary impact is stated, and corrective actions will be submitted within the stipulated period.
Gland Pharma Board Meeting Date
Gland Pharma Ltd scheduled a board meeting for November 06, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026.